Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that drug target validation is one of the most active areas in genomics and drug discovery research today. According to the new DR Report entitled Accelerating Target Validation: Leading Technologies and Platform Development Strategies, critical changes are taking place in the markets and the technologies for target validation. These changes include the integration of various target validation platforms within pharmaceutical companies, the evolution of biotechnology firms from target validation tool providers to drug discovery companies, and the emergence of advanced, higher- throughput target validation approaches. With many more potential targets on hand -- but little information about each individual target -- and growing pressure to show results from investments in genomics technologies and to fill product pipelines, pharmaceutical and genomics companies are focusing on finding the best candidates among thousands of available targets.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

"The need for large-scale target validation will continue over the next five years-until researchers have elucidated the function of most human genes," said Barbara Bolten, analyst at Decision Resources. "During this period, great commercial opportunities will be available to smaller firms that can provide efficient and cost-effective target validation tools and services to pharmaceutical collaborators."

About DR Reports from Decision Resources

DR Reports are extensively researched and comprehensively written research publications that explore development activity, ground-breaking advances, and emerging trends in health care markets. DR Reports are created by engaging experts in the field, conducting extensive secondary research, and synthesizing the findings into a cohesive, well-documented, written analysis. DR Reports cover a wide variety of health care industry concerns, including drug development, therapy markets, diagnostics, health care delivery and economics, and consumer health.

About Decision Resources

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X57486575

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Eli Lilly Hopes to Find New Growth in the Maturing Depression Market with Duloxetine

View Now